Stay updated on Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Sign up to get notified when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.

Latest updates to the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed descriptions of a Phase 2 study for poziotinib in NSCLC, which included participant cohorts and eligibility criteria. Additionally, a new revision number has been added, indicating an update to the document.SummaryDifference29%
- Check15 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check73 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check80 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.